Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 4. Restriction of TCR antigen to hematopoietic tissues does not prevent CAR8 exhaustion and failure of leukemia clearance. Restriction of TCR antigen.

Published byCaroline Neal Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 4. Restriction of TCR antigen to hematopoietic tissues does not prevent CAR8 exhaustion and failure of leukemia clearance. Restriction of TCR antigen."— Presentation transcript:

1 Fig. 4. Restriction of TCR antigen to hematopoietic tissues does not prevent CAR8 exhaustion and failure of leukemia clearance. Restriction of TCR antigen to hematopoietic tissues does not prevent CAR8 exhaustion and failure of leukemia clearance. (A) Female/male hematopoietic chimeras were generated by CD3-depleted bone marrow transplantation 21 days before injection of 1 × 106 E2aPbx followed by lymphodepletion on day −1 and treatment with 1 × 106 CD19 CAR T cells or mock-transduced T cells on day 0. (B and C) Survival of HY-CAR8– or HY-CAR4–treated mice. (D and E) Leukemia burden in the bone marrow 7 days after infusion of CAR T cells. (F and G) PD-1 expression and (H and I) LAG3 expression on HY-CAR8 and HY-CAR4 7 days after infusion [for (B) to (I): *P < 0.05, ****P < (relative to the F→F group), one-way ANOVA performed for all comparisons and log-rank Mantel-Cox test for survival analysis]. Yinmeng Yang et al., Sci Transl Med 2017;9:eaag1209 Published by AAAS

Download ppt "Fig. 4. Restriction of TCR antigen to hematopoietic tissues does not prevent CAR8 exhaustion and failure of leukemia clearance. Restriction of TCR antigen."

Similar presentations

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.
Fig. 1. TP is highly expressed in myeloma.

Fig. 1. TP is highly expressed in myeloma.
Fig. 6. Transgenic expression of αLNNd and mag in dyW/dyW mice improves muscle function, increases body weight, and prolongs life span. Transgenic expression.

Fig. 6. Transgenic expression of αLNNd and mag in dyW/dyW mice improves muscle function, increases body weight, and prolongs life span. Transgenic expression.
Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.
Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.
Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.
Fig. 1. BCAS1 expression identifies newly generated oligodendrocytes.

Fig. 1. BCAS1 expression identifies newly generated oligodendrocytes.
Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.

Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.
Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.

Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.
Fig. 1 Increasing UCB cell dose impairs short-term progenitor cell engraftment. Increasing UCB cell dose impairs short-term progenitor cell engraftment.

Fig. 1 Increasing UCB cell dose impairs short-term progenitor cell engraftment. Increasing UCB cell dose impairs short-term progenitor cell engraftment.
In vivo responses of AMLMLL to ATRi.

In vivo responses of AMLMLL to ATRi.
Fig. 4. Biomechanical properties of treated tibiae.

Fig. 4. Biomechanical properties of treated tibiae.
Fig. 8. In vivo suppression of MM by CMLD

Fig. 8. In vivo suppression of MM by CMLD
Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.
Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade
CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA

CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA
Fig. 1 ZIKV-related flaviviruses cause fetal demise in mice that can be prevented by mAb treatment. ZIKV-related flaviviruses cause fetal demise in mice.

Fig. 1 ZIKV-related flaviviruses cause fetal demise in mice that can be prevented by mAb treatment. ZIKV-related flaviviruses cause fetal demise in mice.
Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Similar presentations

Ads by Google